ClinicalTrials.gg
CompletedNCT01397097Updated Jul 25, 2016

LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study

A Phase 3 interventional study of LNG-IUS (BAY 86-5028) and 68 mg etonorgestrel implant for subdermal use (Nexplanon) in Contraception, sponsored by Bayer. Completed at 43 sites in 6 countries. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2016-07-25.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
766
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The primary objective is to demonstrate that discontinuation rates in women (ages 18-35 years inclusive) using LCS12 are not higher than those seen in women using ENG subdermal implant over a period of 12 months.

Secondary objectives are to observe the bleeding patterns, adverse event profiles and the occurrence of unintended pregnancies. Additionally, data on user satisfaction, IUS expulsions and implant site complications will be collected.

02

Conditions studied

  • Contraception
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated the
  • Healthy female subjects in need of
  • Age: between 18 and 35 years (inclusive) at Screening visit
  • Normal or clinically insignificant cervical smear not requiring further follow up (a cervical smear has to be taken at screening visit or a normal result has to be documented within the previous six months). HPV testing in subjects with ASCUS can be used as an adjunctive test. Subjects with ASCUS can be included if they are negative for high-risk HPV strains.
  • History of regular cyclic menstrual periods as determined by subject's history, subject has regular menstrual cycles (length of cycle 21 - 35 days). (Subject's history while not using hormonal contraceptives is sufficient, no is required).
  • Subject is willing and able to attend the scheduled study visits and to comply with the study procedures.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or currently lactating
  • Vaginal delivery, cesarean delivery or abortion within 6 weeks prior to Screening visit. Note: Postpartum LCS12 insertions should be postponed until uterus is fully involuted, however not earlier than 6 weeks after delivery. If involution is substantially delayed, consider waiting until 12 weeks postpartum.
  • Infected abortion or postpartum endometritis within 3 months prior to the Screening visit.
  • Undiagnosed abnormal genital bleeding.
  • Acute lower genital tract infection (until successfully treated)
  • Acute or history of recurrent, pelvic inflammatory disease.
  • Congenital or acquired uterine anomaly or any distortion of the uterine cavity (e.g. by fibroids) that, in the opinion of the investigator or designee, would cause problems during insertion, retention, or removal of LCS12. (Note: a pre-insertion ultrasound is not necessary. However, if based on subject history or physical exam findings, there is a suspicion of uterine anomaly or any distortion of the uterine cavity, appropriate diagnostic measures should be taken prior to randomization)
  • History of, diagnosed or suspected genital , and untreated cervical dysplasia.
  • endometrial polyp(s) that, in the opinion of the investigator or designee, may interfere with the assessment of the bleeding profile during the study. (Note: a pre-insertion ultrasound is not necessary. However, if based on subject history or physical exam findings, there is a suspicion of polyps, appropriate diagnostic measures should be taken prior to randomization.)
  • Has previously failed screening for this study
  • Any disease or condition that may worsen under hormonal treatment according to the assessment and opinion of the investigator. The following are examples of such conditions or diseases:

    • Cardiovascular
    • Presence or a history of venous or arterial thrombotic/thromboembolic events (e.g., deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a cerebrovascular accident, including prodromi (e.g. , angina pectoris)
    • Repeated measurements of systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg.

Liver

  • Presence or history of liver tumors (benign or malignant)
  • Presence or history of severe hepatic disease as long as liver function values have not returned to normal
  • Jaundice and/or pruritus related to cholestasis (Gilbert's syndrome excepted)
  • History of cholestatic jaundice associated with pregnancy or previous COC use

    • Other diseases:
  • Malignant or premalignant disease (excluding melanoma)
  • History of migraine with focal neurologic symptoms

    • Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results
    • Clinically significant ovarian cyst (defined as abnormal non-functional cysts) (Note: a pre-insertion ultrasound is not necessary. However, if based on subject history or physical exam findings, there is a suspicion of a clinically significant cyst, appropriate diagnostic measures should be taken prior to randomization.)
    • Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism or altered excretion of the study medication
    • Other methods:
  • Sterilization
  • Use of any long-acting injectable sex-hormone preparations within 10 months prior to the Randomization visit. The use of non study oral, vaginal, or transdermal hormonal contraception, intrauterine devices (IUDs) with or without hormonal release, and implants is prohibited during treatment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
766 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: LNG-IUS (BAY 86-5028)

  • Active comparator
    Arm 2

    Drug: 68 mg etonorgestrel implant for subdermal use (Nexplanon)

Interventions

06

What researchers measure

Primary outcomes

  1. Discontinuation rate by treatment group

    Time frame: at 12 months

Secondary outcomes

  1. Discontinuation rates by treatment group

    Time frame: at 6 months and by reason at 6 and 12 months

  2. Overall satisfaction rating and questionnaires on User satisfaction and bleeding and Contraceptive tolerability

    Time frame: at 6 and 12 months

  3. Pregnancy rate, as determined by Pearl index

    Time frame: at 12 months

07

Study locations

43 sites
  • Ashfield, New South Wales 2031, Australia
  • Sydney, New South Wales 2031, Australia
  • North Adelaide, South Australia 5006, Australia
  • Parkville, Victoria 3053, Australia
  • Nedlands, Western Australia 6009, Australia
  • Espoo, 02100, Finland
  • Helsinki, 00100, Finland
  • Helsinki, 00120, Finland
  • Helsinki, 00260, Finland
  • Kuopio, 70110, Finland
  • Tampereen yliopisto, 33014, Finland
  • Tampere, 33100, Finland
  • Turku, 20100, Finland
  • Turku, 20540, Finland
  • Biarritz, 64200, France
  • Bordeaux, 33000, France
  • Marseille, 13005, France
  • Quetigny, 21800, France
  • Reims, 51092, France
  • Schiltigheim, 67300, France
  • Seclin, 59113, France
  • Strasbourg, 67 000, France
  • Elverum, 2403, Norway
  • Haugesund, 5515, Norway
  • Ski, 1400, Norway
  • Straume, 5353, Norway
  • Trondheim, 7014, Norway
  • Göteborg, 411 18, Sweden
  • Göteborg, 416 64, Sweden
  • Linköping, 582 25, Sweden
  • Luleå, 972 33, Sweden
  • Malmö, 205 02, Sweden
  • Malmö, 217 44, Sweden
  • Stockholm, 118 83, Sweden
  • Stockholm, 171 76, Sweden
  • Uppsala, 75185, Sweden
  • Örebro, 701 85, Sweden
  • Cambridge, Cambridgeshire CB5 8DT, United Kingdom
  • Sheffield, South Yorkshire S1 2PJ, United Kingdom
  • Leeds, West Yorkshire LS2 9AE, United Kingdom
  • Liverpool, L20 5DQ, United Kingdom
  • London, SW10 9NH, United Kingdom
  • London, W12 0HS, United Kingdom
08

References and documents

Publications

  • Apter D, Briggs P, Tuppurainen M, Grunert J, Lukkari-Lax E, Rybowski S, Gemzell-Danielsson K. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant. Fertil Steril. 2016 Jul;106(1):151-157.e5. doi: 10.1016/j.fertnstert.2016.02.036. Epub 2016 Mar 24. PubMed 27016644 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Jun 2013 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2011
First posted
Jul 19, 2011
Start
Sep 2011
Primary completionActual
Jun 2013
CompletionActual
Apr 2015
Last update
Jul 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01397097
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 19, 2011
Start date
Sep 2011
Primary completion
Jun 2013
Completion
Apr 2015
Last update
Jul 25, 2016

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levonorgestrel

Start the discussion